1019 ET - Hims & Hers Health is still benefiting from the fact that consumers are struggling to obtain branded weight-loss drugs, known as GLP-1s, TD Cowen analysts say in a research note. The stock has been volatile due to uncertainty around whether Hims can keep offering its compounded GLP-1 after a shortage of branded GLP-1s was resolved, the analysts say. But the environment for GLP-1s is still highly dynamic and Hims' compounded version is still a credible solution for consumers that can't easily get branded GLP-1s, the analysts say. That said, the risk remains that regulators could swoop in at some point with new restrictions around compounded drugs, the analysts say. (dean.seal@wsj.com)
(END) Dow Jones Newswires
November 05, 2024 10:19 ET (15:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。